Mirum Pharmaceuticals (MIRM) Competitors $52.50 -0.66 (-1.24%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$52.44 -0.06 (-0.11%) As of 02/21/2025 05:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends MIRM vs. QGEN, ASND, ROIV, RVMD, LEGN, BBIO, AXSM, BPMC, TLX, and ELANShould you be buying Mirum Pharmaceuticals stock or one of its competitors? The main competitors of Mirum Pharmaceuticals include Qiagen (QGEN), Ascendis Pharma A/S (ASND), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Legend Biotech (LEGN), BridgeBio Pharma (BBIO), Axsome Therapeutics (AXSM), Blueprint Medicines (BPMC), Telix Pharmaceuticals Limited American Depositary Shares (TLX), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry. Mirum Pharmaceuticals vs. Qiagen Ascendis Pharma A/S Roivant Sciences Revolution Medicines Legend Biotech BridgeBio Pharma Axsome Therapeutics Blueprint Medicines Telix Pharmaceuticals Limited American Depositary Shares Elanco Animal Health Qiagen (NYSE:QGEN) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability, media sentiment and community ranking. Does the MarketBeat Community favor QGEN or MIRM? Qiagen received 119 more outperform votes than Mirum Pharmaceuticals when rated by MarketBeat users. However, 75.58% of users gave Mirum Pharmaceuticals an outperform vote while only 60.29% of users gave Qiagen an outperform vote. CompanyUnderperformOutperformQiagenOutperform Votes24960.29% Underperform Votes16439.71% Mirum PharmaceuticalsOutperform Votes13075.58% Underperform Votes4224.42% Which has more risk & volatility, QGEN or MIRM? Qiagen has a beta of 0.36, meaning that its share price is 64% less volatile than the S&P 500. Comparatively, Mirum Pharmaceuticals has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500. Do insiders & institutionals have more ownership in QGEN or MIRM? 70.0% of Qiagen shares are owned by institutional investors. 9.0% of Qiagen shares are owned by insiders. Comparatively, 22.9% of Mirum Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has better valuation and earnings, QGEN or MIRM? Qiagen has higher revenue and earnings than Mirum Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQiagen$1.98B4.43$83.59M$0.36110.03Mirum Pharmaceuticals$307.03M8.21-$163.41M-$2.02-25.99 Do analysts rate QGEN or MIRM? Qiagen currently has a consensus price target of $47.71, suggesting a potential upside of 20.73%. Mirum Pharmaceuticals has a consensus price target of $57.10, suggesting a potential upside of 8.76%. Given Qiagen's higher possible upside, research analysts clearly believe Qiagen is more favorable than Mirum Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qiagen 0 Sell rating(s) 7 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.30Mirum Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09 Is QGEN or MIRM more profitable? Qiagen has a net margin of 4.23% compared to Mirum Pharmaceuticals' net margin of -31.69%. Qiagen's return on equity of 13.92% beat Mirum Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Qiagen4.23% 13.92% 8.40% Mirum Pharmaceuticals -31.69%-41.22%-14.81% Does the media prefer QGEN or MIRM? In the previous week, Qiagen had 5 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 12 mentions for Qiagen and 7 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 0.49 beat Qiagen's score of -0.37 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qiagen 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Mirum Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryQiagen beats Mirum Pharmaceuticals on 11 of the 19 factors compared between the two stocks. Get Mirum Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIRM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MIRM vs. The Competition Export to ExcelMetricMirum PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.52B$7.04B$5.77B$8.99BDividend YieldN/A2.87%4.78%3.85%P/E Ratio-25.996.1326.4618.82Price / Sales8.21311.22453.6978.73Price / CashN/A67.8344.0437.47Price / Book9.856.747.634.64Net Income-$163.41M$138.11M$3.18B$245.69M7 Day Performance4.92%-2.43%-1.91%-2.66%1 Month Performance12.38%-1.91%-0.19%-2.15%1 Year Performance86.05%-5.03%16.70%12.90% Mirum Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MIRMMirum Pharmaceuticals2.6731 of 5 stars$52.50-1.2%$57.10+8.8%+85.6%$2.55B$186.37M0.00140News CoverageQGENQiagen4.4342 of 5 stars$39.85-0.5%$48.78+22.4%-5.2%$8.84B$1.98B110.975,967Analyst DowngradeASNDAscendis Pharma A/S3.1849 of 5 stars$144.08+1.1%$193.43+34.3%-3.0%$8.74B$288.08M-17.83640Analyst ForecastROIVRoivant Sciences2.7497 of 5 stars$10.56+1.1%$18.08+71.2%-7.5%$7.69B$122.59M1.87860Insider TradeRVMDRevolution Medicines4.5121 of 5 stars$40.67-1.6%$66.25+62.9%+41.7%$6.84B$11.58M-11.33250Positive NewsLEGNLegend Biotech2.5994 of 5 stars$36.42+0.1%$79.50+118.3%-33.7%$6.65B$285.14M-38.341,800News CoveragePositive NewsBBIOBridgeBio Pharma4.7202 of 5 stars$34.90+10.6%$49.08+40.6%+7.9%$6.60B$9.30M-14.48400Earnings ReportAnalyst ForecastInsider TradeNews CoverageGap UpAXSMAxsome Therapeutics4.5314 of 5 stars$131.15-0.4%$147.13+12.2%+67.8%$6.36B$270.60M-20.08380Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageBPMCBlueprint Medicines3.0033 of 5 stars$93.94-1.3%$123.83+31.8%+5.7%$5.97B$249.38M-44.52640Earnings ReportAnalyst UpgradeTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$17.19-0.6%$22.00+28.0%N/A$5.79B$637.08M0.00N/ANews CoverageGap UpELANElanco Animal Health4.057 of 5 stars$11.26-3.4%$16.29+44.7%-31.9%$5.57B$4.42B28.159,300Analyst Forecast Related Companies and Tools Related Companies Qiagen Competitors Ascendis Pharma A/S Competitors Roivant Sciences Competitors Revolution Medicines Competitors Legend Biotech Competitors BridgeBio Pharma Competitors Axsome Therapeutics Competitors Blueprint Medicines Competitors Telix Pharmaceuticals Limited American Depositary Shares Competitors Elanco Animal Health Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MIRM) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredHow to trade Executive Order 14154Trump’s pen must be running out of ink… Since he returned to office he’s signed more than 50 Executive Orde...Porter & Company | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mirum Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mirum Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MIRM Stock Alerts